ConductScience.org, home

Paper42787250PubMed

Comparison of efficacy and safety of systemic glucocorticoids and Nefecon in IgA nephropathy patients: a real-world retrospective cohort study.

Gu C and 3 others. Front Immunol, 2026.

Cite this record

ConductScience Library. Comparison of efficacy and safety of systemic glucocorticoids and Nefecon in IgA nephropathy patients: a real-world retrospective cohort study. Papers, record 42787250. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42787250

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Comparison of efficacy and safety of systemic glucocorticoids and Nefecon in IgA nephropathy patients: a real-world retrospective cohort study.
Journal
Front Immunol
Year
2026
Publication types
Journal Article, Comparative Study, Research Support, Non-U.S. Gov't
Revised in PubMed
2026-10-27

Source PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Gu CChenjie
2Zhou JJingying
3Kang LLe
4Fang MMing

Source PubMed

Download CSV of authors

Topics12

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Glomerulonephritis, IGAMajor topic
GlucocorticoidsMajor topic
Humans
Female
Male
Adult
Retrospective Studies
Treatment Outcome
Glomerular Filtration Rate
Middle Aged
Remission Induction
Proteinuria

Source PubMed

Download CSV of topics

References22

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
140975564KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV).Kidney Int2025https://conductscience.org/library/papers/40975564PubMed
236270561
Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy.
Kidney Int2023https://conductscience.org/library/papers/36270561PubMed
333309134IgA Nephropathy: An Interesting Autoimmune Kidney Disease.Am J Med Sci2021https://conductscience.org/library/papers/33309134PubMed
439291217Exploring Novel Adverse Events of Nefecon.Kidney Int Rep2024https://conductscience.org/library/papers/39291217PubMed
535579642Effect of Oral Methylprednisolone on Decline in Kidney Function or Kidney Failure in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial.JAMA2022https://conductscience.org/library/papers/35579642PubMed
640678796Predictive value of Gd-IgA1, poly-IgA in the treatment of IgA nephropathy with targeted-release formulation budesonide.Clin Kidney J2025https://conductscience.org/library/papers/40678796PubMed
740061933Targeted-release budesonide: A comprehensive review on its potential in IgA nephropathy.Heliyon2025https://conductscience.org/library/papers/40061933PubMed
839518760IgA Vasculitis (Henoch-Schönlein Purpura): An Update on Treatment.J Clin Med2024https://conductscience.org/library/papers/39518760PubMed
937591292Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial.Lancet2023https://conductscience.org/library/papers/37591292PubMed
1039232245The pathogenesis of IgA nephropathy and implications for treatment.Nat Rev Nephrol2025https://conductscience.org/library/papers/39232245PubMed
1139211339Therapy of IgA nephropathy: time for a paradigm change.Front Med (Lausanne)2024https://conductscience.org/library/papers/39211339PubMed
1221949093The pathophysiology of IgA nephropathy.J Am Soc Nephrol2011https://conductscience.org/library/papers/21949093PubMed
1328159829IgA Nephropathy.Clin J Am Soc Nephrol2017https://conductscience.org/library/papers/28159829PubMed
1437103889Budesonide delayed-release capsules to reduce proteinuria in adults with primary immunoglobulin A nephropathy.Expert Rev Clin Immunol2023https://conductscience.org/library/papers/37103889PubMed
1518838301How host-bacterial interactions lead to IgA synthesis in the gut.Trends Immunol2008https://conductscience.org/library/papers/18838301PubMed
1640235631eGFR slope modelling predicts long-term clinical benefit with nefecon in a real-world IgAN population.Clin Kidney J2025https://conductscience.org/library/papers/40235631PubMed
1741727461Efficacy and safety of Nefecon in IgA nephropathy: real world clinical practice.Front Immunol2026https://conductscience.org/library/papers/41727461PubMed
1841244638The 2025 KDIGO IgA nephropathy guideline update: an ERA Immunonephrology Working Group perspective.Clin Kidney J2025https://conductscience.org/library/papers/41244638PubMed
1938036542IgA nephropathy.Nat Rev Dis Primers2023https://conductscience.org/library/papers/38036542PubMed
2040828437Clinical risk assessment of serum creatinine abnormalities during vancomycin therapy: a retrospective study using machine learning models.Int J Clin Pharm2025https://conductscience.org/library/papers/40828437PubMed

See all 22 referencesDownload CSV of references

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Cited by
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/42787250

GET https://conductscience.org/api/papers/v1/42787250/references?page=2